FindMyKOL
Clinical trialNCT01203839Active, not recruitingPhase 2Interventional

Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer

SponsorMemorial Sloan Kettering Cancer CenterEnrollment110Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Currently the standard of care is to treat early stage invasive breast cancer or ductal carcinoma in situ (DCIS) with a combination of lumpectomy and radiotherapy, known as "breast-conserving therapy" (BCT). The traditional method of giving radiation therapy after a lumpectomy is to the whole breast. However the investigators do not know if the whole breast needs to be receive radiation to better control your cancer or only a more limited area of the breast surrounding the tumor. The purpose of this study is to see the side effects of delivering partial breast irradiation (PBI) instead of whole breast irradiation (WBI). PBI is radiation therapy given only to the area of the breast where the cancer was removed. Another purpose of this study is to look long term at the rate at which cancer comes back in the same breast after PBI. WBI is radiation therapy given 5 days a week for 5 to 7 weeks to the whole breast. Partial breast irradiation radiation therapy (PBI) is much shorter than whole breast irradiation. The investigators propose to deliver the PBI radiation therapy, for a few minutes a day, once a day, five days a week, for 2 weeks. In this study the investigators will learn about the good and bad effects of PBI radiation therapy. In this study, the investigators will also learn about how the breast looks after surgery and radiation therapy.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Memorial Sloan Kettering at Basking Ridge (follow-Up Only)

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Monmouth (follow-Up Only)

    Middletown, New Jersey, United States

  • Memorial Sloan Kettering Bergen (follow-Up Only)

    Montvale, New Jersey, United States

  • Memorial Sloan Kettering Cancer Center @ Suffolk (follow-Up Only)

    Commack, New York, United States

  • Memorial Sloan Kettering Westchester (follow-Up Only)

    Harrison, New York, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

  • Memorial Sloan Kettering at Mercy Medical Center (follow-Up Only)

    Rockville Centre, New York, United States

  • Memorial Sloan Kettering Nassau

    Uniondale, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Sept 2010
Primary completion
30 Sept 2026
Completion
30 Sept 2026
Last update posted
6 Oct 2025
Registered enrollment
110
Registry id
NCT01203839

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.